A shares can travel all over the world with “lithium”.
On the morning of December 29, the price of lithium carbonate exceeded 300000 yuan / ton, driving the sharp rise of lithium mining and lithium extraction from Salt Lake, Yongxing Special Materials Technology Co.Ltd(002756) and cangge mining reached an all-time high. Another super track, the cro plate has an active trend and has rebounded continuously in the past two trading days.
Baijiu plate has been sharply callback, Kweichow Moutai Co.Ltd(600519) and Wuliangye Yibin Co.Ltd(000858) have dropped more than 4%.
The total turnover of A-Shares this year has steadily exceeded in 2015
At the closing on the morning of the 29th, the three major A-share indexes fell collectively, of which the Shanghai Composite Index fell 0.79% to 3601.54 points; The Shenzhen composite index fell 1.13% to 14670.20 points; The gem index fell 1.29% to 3285.52.
It is worth noting that this morning, A-share Shanghai and Shenzhen markets traded a total of 638.7 billion yuan. So far, the total turnover in 2021 has steadily exceeded 253.3 trillion in 2015 (2015 was the previous highest year), a record high.
From July 21 to September 29 this year, the turnover of Shanghai and Shenzhen stock markets exceeded trillion yuan for 49 consecutive trading days, the highest in history, exceeding that of 43 consecutive trading days in 2015, and the turnover of Shanghai and Shenzhen stock markets exceeded trillion yuan for 46 consecutive trading days from October 22 to December 24.
A-Shares have “lithium” again
On the morning of December 29, the two sectors of A-share lithium mine and salt lake lithium extraction continued yesterday’s rebound trend, and the intraday share prices of Yongxing Special Materials Technology Co.Ltd(002756) and Zanger mining reached a record high. Last Friday Contemporary Amperex Technology Co.Limited(300750) fell sharply. The market once had a pessimistic view on the lithium battery industry chain. Why has the market attitude changed significantly now? Source: East Money Information Co.Ltd(300059)
Zoomlion data show that the price of lithium carbonate has exceeded 300000 yuan / ton this morning. From: Zoomlion app
Guotai Junan Securities Co.Ltd(601211) firmly optimistic that this round of lithium price has a certain sustainability at a high level, rather than pure cyclical ups and downs. According to the current investigation, we know that the lithium carbonate Library in the three yuan material factory has more than 1 months, and lithium iron phosphate consumption is only 2-3 weeks. Next year, the global lithium resources will total about 180000 tons of LCE (lithium carbonate equivalent). In addition, lithium ore needs at least 3-5 years from mining, exploration to production, and the future probability is still in tight balance.
Citic Securities Company Limited(600030) it is expected that the lithium price will remain high in 2022, and the price inflection point will not appear in the short term. The lithium salt price center in 2022 will be significantly higher than that in 2021, which will drive the company’s performance of the lithium sector to increase significantly. The valuation advantage and configuration value of the lithium sector in 2022 are high.
cro plate rebounded continuously
Recently, another super track cro plate in the A-share market has also begun to become active.
On the morning of December 29, the cro sector index rose by more than 1%, and individual stocks such as Wuhan Hiteck Biological Pharma Co.Ltd(300683) , Chempartner Pharmatech Co.Ltd(300149) in the sector rose significantly. Source: East Money Information Co.Ltd(300059)
The overall trend of cro sector is poor this year. Leading stocks Wuxi Apptec Co.Ltd(603259) rarely fell by the limit on December 15.
Zheshang Securities Co.Ltd(601878) said that from 2015 to 2021, the investment and financing amount of global innovative drugs continued to reach a new high, laying the foundation for the excess return of clinical cro leaders. The performance of clinical cros outside China – Valuation – stock price is highly correlated, and the project management experience and ability to obtain orders in different disease fields will bring a significant premium. The valuation and increase of Chinese clinical cros such as Hangzhou Tigermed Consulting Co.Ltd(300347) are much higher than those of overseas leaders. On the one hand, they come from the high growth of performance, on the other hand, they reflect the local demand and the expectation of sustained high growth of performance. Their management experience, number of outlets and profitability have great room for growth. They maintain the key recommendation of Chinese clinical cro companies.
Minsheng Securities said that the competition pattern of “pharmaceutical + clinical” comprehensive cro is relatively scattered, and has not yet formed an absolute subdivision leader. The volume of each company is small, the penetration rate is limited, and the follow-up growth space and potential are sufficient. At the same time, this type of cro enterprises are also overweight in the field of innovative drugs to improve the ceiling of the industry.
(China Securities Journal)
